Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCS.L Regulatory News (SCS)

  • There is currently no data for SCS

Interim Trading Update

3 Feb 2022 07:00

RNS Number : 5047A
ScS Group PLC
03 February 2022
 

For Immediate Release

3 February 2022

 

 

ScS Group plc

("ScS", or the "Group")

Interim Trading Update

Significant order book growth and robust trading

ScS, one of the UK's largest retailers of upholstered furniture and flooring, today issues the following trading update for the 26 weeks ended 29 January 2022, ahead of its interim results.

 

The Group traded well through the important winter sale period and order intake for the first half of the year was in line with the Board's expectations, with one year like-for-like order intake growth of 16.6%. Two year like-for-like order intake is in line with that achieved in the pre-pandemic 26 week period to 25 January 2020.

 

The Group's online offering and appeal to customers continues to strengthen, with online order growth of 55.8% compared to the equivalent 26 week period to 25 January 2020.

 

The Group's order book has grown significantly against previous comparative periods, driven by the ongoing demand and supply chain challenges which have extended product lead times. As at 29 January 2022, the Group's order book is double the size it was at 25 January 2020, at ÂŁ148.0m. The Group is working closely with suppliers to mitigate the risk of continued supply chain disruption in the second half of the financial year.

 

The Board is pleased with the Group's bookings performance to date and it remains on track to meet full year expectations.

 

ScS expects to announce its interim results on Tuesday, 22 March 2022. A meeting for analysts will be held on the morning of the results, please contact Buchanan via scs@buchanan.uk.com for further details.

 

Enquiries:

ScS Group PLC

Steve Carson, Chief Executive Officer

Chris Muir, Chief Financial Officer

c/o Buchanan +44 (0)20 7466 5000

Buchanan

Richard Oldworth

Victoria Hayns

Tilly Abraham

Tel: +44 (0)20 7466 5000

scs@buchanan.uk.com

Shore Capital

Patrick Castle

James Thomas

Tel: +44 (0)20 7408 4050

 

Notes to Editors

ScS is one of the UK's largest retailers of upholstered furniture and flooring, promoting itself as the "Sofa Carpet Specialist", seeking to offer value and choice through a wide range of upholstered furniture and flooring products. The Group's product range is designed to appeal to a broad customer base with a mid-market priced offering and is currently traded from 99 stores.

 

The Group's upholstered furniture business specialises primarily in fabric and leather sofas and chairs. ScS sells a range of branded products which are not sold under registered trademarks and a range of branded products which are sold under registered trademarks owned by ScS (such as Endurance, Inspire and SiSi Italia). The Group also offers a range of third party brands (which include La-Z-Boy and G Plan). The Group's flooring business includes carpets, as well as laminate and vinyl flooring.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTXLLFBLLLLBBZ
Date   Source Headline
21st Nov 20074:00 pmRNSResults of Meetings
21st Nov 20072:39 pmRNSNet Asset Value(s)
20th Nov 20073:05 pmRNSNet Asset Value(s)
19th Nov 20074:21 pmRNSNet Asset Value(s)
16th Nov 20074:20 pmRNSNet Asset Value(s)
15th Nov 20074:42 pmRNSNet Asset Value(s)
14th Nov 20074:36 pmRNSNet Asset Value(s)
13th Nov 20074:42 pmRNSNet Asset Value(s)
12th Nov 20076:12 pmRNSNet Asset Value(s)-Amendment
12th Nov 20072:57 pmRNSNet Asset Value(s)
9th Nov 200712:43 pmRNSNet Asset Value(s)
8th Nov 20071:28 pmRNSNet Asset Value(s)
7th Nov 20073:16 pmRNSNet Asset Value(s)
6th Nov 20071:09 pmRNSNet Asset Value(s)
5th Nov 20071:33 pmRNSNet Asset Value(s)
2nd Nov 20071:52 pmRNSNet Asset Value(s)
2nd Nov 200711:47 amRNSPortfolio Update
1st Nov 20072:27 pmRNSNet Asset Value(s)
31st Oct 20071:44 pmRNSNet Asset Value(s)
30th Oct 20074:37 pmRNSNet Asset Value(s)
29th Oct 20073:51 pmRNSNet Asset Value(s)
26th Oct 20073:47 pmRNSNet Asset Value(s)
25th Oct 20075:09 pmRNSNet Asset Value(s)
25th Oct 20074:05 pmRNSRollover Proposals
24th Oct 20075:26 pmRNSDividend Declaration
24th Oct 20074:25 pmRNSNet Asset Value(s)
23rd Oct 20073:38 pmRNSNet Asset Value(s)
22nd Oct 20073:26 pmRNSNet Asset Value(s)
19th Oct 20074:12 pmRNSNet Asset Value(s)
18th Oct 20071:56 pmRNSNet Asset Value(s)
17th Oct 200712:59 pmRNSNet Asset Value(s)
16th Oct 20073:28 pmRNSNet Asset Value(s)
15th Oct 20072:57 pmRNSNet Asset Value(s)
12th Oct 20074:06 pmRNSNet Asset Value(s)
11th Oct 20073:25 pmRNSNet Asset Value(s)
10th Oct 20071:42 pmRNSNet Asset Value(s)
9th Oct 20073:27 pmRNSNet Asset Value(s)
8th Oct 20073:00 pmRNSNet Asset Value(s)
5th Oct 20071:43 pmRNSNet Asset Value(s)
4th Oct 20071:45 pmRNSNet Asset Value(s)
3rd Oct 20071:56 pmRNSNet Asset Value(s)
2nd Oct 20072:31 pmRNSNet Asset Value(s)
1st Oct 20071:15 pmRNSNet Asset Value(s)
28th Sep 200712:08 pmRNSNet Asset Value(s)
27th Sep 20073:11 pmRNSNet Asset Value(s)
26th Sep 200712:26 pmRNSNet Asset Value(s)
25th Sep 200711:48 amRNSNet Asset Value(s)
24th Sep 200712:29 pmRNSNet Asset Value(s)
21st Sep 200712:45 pmRNSNet Asset Value(s)
20th Sep 20073:42 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.